Lataa...
Management of metastatic castration-resistant prostate cancer
The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forward in the last 2 years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel, and abiraterone acetate), and a significant delay in skeletal...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3685202/ https://ncbi.nlm.nih.gov/pubmed/23789039 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|